Pulse Biosciences Inc. (PLSE)
16.52
0.86 (5.49%)
At close: Mar 28, 2025, 3:59 PM
17.08
3.39%
Pre-market: Mar 31, 2025, 04:01 AM EDT
5.49% (1D)
| Bid | 15.36 |
| Market Cap | 1.02B |
| Revenue (ttm) | 1.75M |
| Net Income (ttm) | -46.47M |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -19.9 |
| Forward PE | -21.48 |
| Analyst | n/a |
| Ask | 18 |
| Volume | 445,028 |
| Avg. Volume (20D) | 165,090 |
| Open | 16.36 |
| Previous Close | 15.66 |
| Day's Range | 15.87 - 17.67 |
| 52-Week Range | 6.59 - 25.00 |
| Beta | 1.63 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed i...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date May 18, 2016
Employees 56
Stock Exchange NASDAQ
Ticker Symbol PLSE
Website https://www.pulsebiosciences.com
3 days ago
+6%
Pulse Biosciences shares are trading higher. The c...
Unlock content with
Pro Subscription
1 month ago
+14.86%
Pulse Biosciences shares are trading higher after the company announced it appointed a new CFO.
2 months ago · businesswire.com
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceMIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans ...